CDKL2 was recognized as a novel regulator of epithelial-mesenchymal transition (EMT) and demonstrated to enhance mesenchymal traits and stem-cell like phenotypes of breast cancer cells [17]. The gene discussed is CDKL2; the disease is breast carcinoma.